Skip to Content
Merck
  • Radiation promotes malignant phenotypes through SRC in breast cancer cells.

Radiation promotes malignant phenotypes through SRC in breast cancer cells.

Cancer science (2014-12-24)
Rae-Kwon Kim, Yan-Hong Cui, Ki-Chun Yoo, In-Gyu Kim, Minyoung Lee, Yung Hyun Choi, Yongjoon Suh, Su-Jae Lee
ABSTRACT

Despite the fact that ionizing radiation (IR) is widely used as a standard treatment for breast cancer, much evidence suggests that IR paradoxically promotes cancer malignancy. However, the molecular mechanisms underlying radiation-induced cancer progression remain obscure. Here, we report that irradiation activates SRC signaling among SRC family kinase proteins, thereby promoting malignant phenotypes such as invasiveness, expansion of the cancer stem-like cell population, and resistance to anticancer agents in breast cancer cells. Importantly, radiation-activated SRC induced SLUG expression and caused epithelial-mesenchymal cell transition through phosphatidylinositol 3-kinase/protein kinase B and p38 MAPK signaling. In agreement, either inhibition of SRC or downstream signaling of p38 MAPK or protein kinase B effectively attenuated radiation-induced epithelial-mesenchymal cell transition along with an increase in the cancer stem-like cell population. In addition, downregulation of SRC also abolished radiation-acquired resistance of breast cancer cells to anticancer agents such as cisplatin, etoposide, paclitaxel, and IR. Taken together, our findings suggest that combining radiotherapy with targeting of SRC might attenuate the harmful effects of radiation and enhance the efficacy of breast cancer treatment.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Sigma-Aldrich
LY 294002, LY294002, CAS 154447-36-6, is a cell-permeable, potent, reversible, and specific inhibitor of PI 3-kinase ((IC50 = 1.4 µM). Acts on the ATP-binding site.
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard
USP
Transplatin, United States Pharmacopeia (USP) Reference Standard
Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Cisplatin, Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation.
Sigma-Aldrich
Etoposide, A cell-permeable derivative of podophyllotoxin that acts as a topoisomerase II inhibitor (IC50 = 59.2 µM) has major activity against a number of tumors, including germ cell neoplasms, small cell lung cancer, and malignant lymphoma.
Sigma-Aldrich
Anti-ZEB1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Etoposide, synthetic, 95.0-105.0%, powder
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
trans-Platinum(II)diammine dichloride
Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline
Cisplatin, European Pharmacopoeia (EP) Reference Standard
Etoposide, European Pharmacopoeia (EP) Reference Standard